Onconetix, Inc.
$0.73
▼
-18.94%
2026-04-21 08:38:00
www.onconetix.com
NCM: ONCO
Explore Onconetix, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$0.51 M
Current Price
$0.73
52W High / Low
$74.3 / $0.67
Stock P/E
—
Book Value
$50.53
Dividend Yield
—
ROCE
-40.18%
ROE
-1.15%
Face Value
—
EPS
$-82.8
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
2
Beta
3.63
Debt / Equity
0.31
Current Ratio
0.66
Quick Ratio
0.65
Forward P/E
-1.28
Price / Sales
0.96
Enterprise Value
$-4.39 M
EV / EBITDA
0.69
EV / Revenue
-5.38
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | EyePoint, Inc. | $15.07 | — | $1.26 B | — | -74.45% | -72.19% | $19.11 / $5.3 | $3.7 |
| 2. | Senti Biosciences, Inc. | $1.14 | — | $34.26 M | — | -171.08% | -2.18% | $5.1 / $0.77 | $0.18 |
| 3. | Veru Inc. | $2.43 | — | $39 M | — | -161.13% | -60.25% | $7.4 / $2.06 | $2.31 |
| 4. | Acrivon Therapeutics, Inc. | $1.86 | — | $68.97 M | — | -73.75% | -53.86% | $3.56 / $1.05 | $3.56 |
| 5. | Skye Bioscience, Inc. | $0.78 | — | $26.15 M | — | -289.25% | -1.27% | $5.75 / $0.57 | $0.6 |
| 6. | Inovio Pharmaceuticals, Inc. | $1.18 | — | $96.69 M | — | -283.35% | -1.83% | $2.98 / $1.03 | $0.35 |
| 7. | Korro Bio, Inc. | $14.28 | — | $207.54 M | — | -85.99% | -1.11% | $55.89 / $5.2 | $5.46 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.3 M | 0.3 M | 0.11 M | 0.1 M | 0.71 M | — |
| Operating Profit | -1.28 M | -2.07 M | -1.34 M | -1.65 M | -1.97 M | — |
| Net Profit | 5.67 M | -8.78 M | -2.37 M | -8.55 M | -29.44 M | — |
| EPS in Rs | 8.18 | -12.68 | -3.42 | -12.33 | -42.48 | -1,245.4 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.82 M | 2.52 M | 0.06 M | 0 M |
| Operating Profit | -6.34 M | -10.33 M | -17.85 M | -13.48 M |
| Net Profit | -14.03 M | -58.69 M | -37.41 M | -13.42 M |
| EPS in Rs | -20.25 | -84.7 | -53.99 | -19.37 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 24.93 M | 28.18 M | 87.52 M | 26.31 M |
| Total Liabilities | 9.16 M | 18.57 M | 86.11 M | 3.92 M |
| Equity | 15.77 M | 9.61 M | -5.6 M | 22.39 M |
| Current Assets | 6.07 M | 0.95 M | 5.84 M | 26.26 M |
| Current Liabilities | 9.14 M | 18.29 M | 17.19 M | 3.92 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -9.68 M | -10.5 M | -13.58 M | -8.68 M |
| Investing CF | 0 M | -0.03 M | -8.65 M | -0.03 M |
| Financing CF | 14.45 M | 6.74 M | 1.04 M | 32.53 M |
| Free CF | -9.68 M | -10.52 M | -13.64 M | -8.68 M |
| Capex | — | -0.03 M | -0.06 M | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 4217.31% | — | — | — |
| Earnings Growth % | -56.89% | -178.76% | — | — |
| Profit Margin % | -2325.21% | -63986.48% | — | — |
| Operating Margin % | -409.3% | -30526.38% | — | — |
| Gross Margin % | 41.8% | -1927.93% | — | — |
| EBITDA Margin % | -2281.88% | -62784.1% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-03-25 | 1:0.2 |
| 2025-06-13 | 1:0.0117647 |
| 2024-09-24 | 1:0.025 |